Detalles de la búsqueda
1.
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Blood;
2024 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38551812
2.
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma.
Int J Mol Sci;
24(9)2023 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37176092
3.
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.
Int J Mol Sci;
24(12)2023 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37373078
4.
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome.
Int J Mol Sci;
24(10)2023 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37240197
5.
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Blood;
135(26): 2375-2387, 2020 06 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32299093
6.
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Blood;
136(2): 199-209, 2020 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32325491
7.
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.
Hematol Oncol;
40(5): 987-998, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35794705
8.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol;
40(5): 1009-1019, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35638723
9.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol;
40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
10.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol;
108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
11.
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility.
J Transl Med;
19(1): 79, 2021 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33596963
12.
Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
Int J Mol Sci;
22(12)2021 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34200673
13.
Immunologic characterization of COVID-19 patients with hematological cancer.
Haematologica;
106(5): 1457-1460, 2020 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33327714
14.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica;
106(1): 291-294, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107338
15.
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer.
Pancreatology;
16(2): 249-58, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26852170
16.
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Am J Hematol;
96(5): E168-E171, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33580969
17.
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.
Cancer Immunol Immunother;
64(9): 1159-73, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26031574
18.
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
J Cell Physiol;
229(12): 2106-16, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24819167
19.
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.
J Cell Physiol;
228(7): 1506-15, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23254643
20.
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.
Hematol Rep;
15(1): 23-49, 2023 Jan 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648882